February 2025 – Page 14

Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma

2 months ago talkbio0Tagged Acquisition, Asarina, asset, CNS disorder, Neurosteroids, Pharma, Phase 2b, Pregnanolone, (3beta, 5alpha)-isomer, Relmada, Tourette 's syndrome

Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders

Pliant Therapeutics Halts Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial Following Safety Committee Recommendation

2 months ago talkbio0Tagged BEACON-IPF, bexotegrast, Clinical Trials, Data Safety, Idiopathic Pulmonary Fibrosis, Pliant

Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis (IPF), BEACON-IPF trial, clinical trial suspension, Data Safety Monitoring Board (DSMB)

Pliant Therapeutics Halts Key Fibrosis Drug Trial, Stock Plummets Amid Uncertainty

2 months ago talkbio0Tagged BEACON-IPF, bexotegrast, Clinical Trials, crash, Data Safety, Idiopathic Pulmonary Fibrosis, Pliant, Preventive monitoring

Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis, BEACON-IPF trial, clinical trial pause, stock crash, Data Safety Monitoring Board

Roivant Halts Lung Disease Drug Development as Bio-Thera and Intas Forge Biosimilar Partnership

2 months ago talkbio0Tagged Accord BioPharma, Bio-Thera, Biopharma, Biosimilars, golimumab, Intas, namilumab, Roivant, Sarcoidosis, Pulmonary, Solutions

Roivant Sciences, namilumab, pulmonary sarcoidosis, Bio-Thera Solutions, Intas Pharmaceuticals, golimumab biosimilar, BAT2506, Accord BioPharma

FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections

2 months ago talkbio0Tagged AbbVie, Antibiotic Resistance, Microbial, avibactam, aztreonam, Emblaveo, Gram-negative bacteria, intra-abdominal infections

Emblaveo, aztreonam, avibactam, antibiotic resistance, Gram-negative bacteria, intra-abdominal infections, AbbVie

Sionna Therapeutics Raises $191M in Upsized IPO, Aardvark Therapeutics Aims for $100M Listing

2 months ago talkbio0Tagged biotech, Cystic Fibrosis, IPOs, Metabolic Diseases, Nasdaq, Obesity, Order Tubulidentata (organism)

Biotech IPOs, Sionna Therapeutics, Aardvark Therapeutics, Cystic Fibrosis, Metabolic Diseases, NASDAQ, Obesity Treatment

Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial

2 months ago talkbio0Tagged Autoimmune Diseases, Gazyva, Lupus Nephritis, obinutuzumab, Phase III REGENCY trial, Renal function, renal response, Roche (company)

Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function

Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment

3 months ago talkbio0Tagged Acquisition, Bain Capital, carve-out, Drug Industry, Investments, Japanese language, Mitsubishi, Private Equity, Transaction

Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment